Últimas subidas - Age-Related Macular Degeneration - Wet
|
Conversion to Wet AMD after Izervayvista 36 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 40 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 35 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 48 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 39 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 31 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 41 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 36 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 42 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 35 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 37 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 33 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 44 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 37 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 33 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 35 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Conversion to Wet AMD after Izervayvista 38 veces83 year old man whose left eye had minimal GA and converted from dry to wet AMD after a single Izervay treatmentMarzo 15, 2026
|
|
Peripapillary CNVM No Treatmentvista 60 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 35 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 43 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 42 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 29 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 35 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 43 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 46 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 38 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 36 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 33 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 26 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 37 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 29 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 35 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 40 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 35 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 35 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 43 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 47 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 38 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 39 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 39 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 42 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 43 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 27 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 44 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 40 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Peripapillary CNVM No Treatmentvista 37 veces85 year old with peripapillary CNVM watched for many years.Febrero 18, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 48 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 56 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 48 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 61 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 49 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 57 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 48 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 53 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 43 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 46 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 54 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 48 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 60 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 48 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 48 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 57 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 54 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Post Anti-VEGF RPE Tear (Vabysmo)vista 59 veces87 year old female with vision loss OS (20/125) given 1/4 dose vabysmo and developed RPE tear VA dropped to 20/400Enero 11, 2026
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 166 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 152 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 141 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 143 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 130 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 149 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 154 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 138 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 128 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 159 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 134 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 137 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 108 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 107 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 86 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 96 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 89 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 79 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Idiopathic Polypoidal Choroidal Vasculopathyvista 112 veces83 year old man with wet AMD for 12 years resistant to Anti-VEGF therapy but responsive to PDTFebrero 12, 2025
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 102 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 108 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 86 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 94 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 93 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 86 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 77 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 93 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 93 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 111 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 107 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 95 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 87 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 96 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 120 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 71 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
Wet AMD - Occult CNVM and Geographic atrophyvista 104 veces77 year old female with mild vision loss - 20/32 - responded to AvastinDiciembre 19, 2024
|
|
| 1175 archivos en 12 página(s) |
1 |
 |
|
|
|
|
|
|
|
|
|
